Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development
Author:
Jearanaiwitayakul Tuksin,
Sunintaboon Panya,
Kittiayuwat AnuwatORCID,
Limthongkul Jitra,
Wathanaphol Jidapar,
Janhirun YadaORCID,
Lerdsamran Hatairat,
Wiriyarat Witthawat,
Ubol Sukathida
Reference46 articles.
1. SARS-CoV-2 new variant BF.7: a new public threat globally, symptoms, precautions, transmission rate, and futures perspective - correspondence;Rahman;Int J Surg,2023
2. Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening;Hu;Virus Res,2022
3. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs;Lee;Nat Commun,2020
4. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape;Tregoning;Nat Rev Immunol,2021
5. Chakraborty C, Bhattacharya M, Sharma AR, Mallik B. Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol. 2022;219:980-97.